Prevalence and Predictors of Metabolic Syndrome in Polycystic Ovarian Syndrome in Uttarakhand

  • Manju Lal Associate Professor, Department of Obstetrics and Gynaecology, Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun, Uttarakhand, India.
  • Priyanka Goyal Senior Resident, Department of Obstetrics and Gynaecology, Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun, Uttarakhand, India.
  • Saba Shamim MS Scholar, Department of Obstetrics and Gynaecology, Himalayan Institute of Medical Sciences, Jolly Grant, Dehradun, Uttarakhand, India.
Keywords: Polycystic ovarian syndrome, Metabolic syndrome, Prevalence

Abstract

Background: Woman with polycystic ovarian syndrome (PCOS) are at increased risk of developing Metabolic syndrome (MS). MS is a clustering of factors known to increase the risk of diabetes mellitus and cardiovascular disease. Aim of this present study was to determine the prevalence and predictors of MS in PCOS women of Uttarakhand. Methods: This prospective observational study was conducted in department of Obtstetrics & Gynecology, SHRU from May 2016 till May 2017. A total of 200 women, diagnosed with PCOS between the ages of 15-40years were involved (by Rotterdam’s criteria). Clinical and biochemical parameters for MS, were defined by National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. Statistical analysis were performed with descriptive analytical methods using SPSS software version 16. Results: The prevalence of MS in PCOS was 22  (44 cases). The rate of central obesity, FBS more than 110mg/dl, triglycerides more than 150mg/dl, high density lipoproteins cholesterol levels (HDL-C) less than 50mg/dl and blood pressure ≥130/85mmHg in PCOS women were 30  (60), 3.5 (7), 34 (68), 70 (140) and 11 (22), respectively.  PCOS has evolved as a risk factor for endocrinal and metabolic derangements. Conclusions: Special strategies are required to prevent MS and its associated complications in PCOS women.

Downloads

Download data is not yet available.

References

1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine. 2010; 8: 41
2. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41-47.
3. Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN, et al. Metabolic profiles characterizing different phenotypes of poly-cystic ovary syndrome: plasma metabolomics analysis. BMC Med. 2012; 10: 153.
4. Oliveira Rdo S, Redorat RG, Ziehe GH, Mansur VA, Conceição FL. Arterial hypertension and metabolic profile in patients with polycystic ovary syndrome. Rev Bras Ginecol Obstet. 2013; 35(1): 21-26.
5. Hughes C, Elgasim M, Layfield R, Atiomo W. Genomic and post-genomic approaches to polycystic ovary syndrome-progress so far: mini review. Hum Reprod. 2006; 21(11): 2766-2775.
6. Diamanti-Kandarakis E, Piperi C, Spina J, Argyrakopoulou Argyrakopoulou G, Papanastasiou L, Bergiele A, et al. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens). 2006; 5(1): 17-34.
7. Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implica-tions. Expert Rev Mol Med. 2008; 10: e3
8. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res. 2010; 131: 743-760
9. Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J ClinEndo-crinolMetab. 2002; 87(9): 4085-4087
10. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detectionevaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report.Circulation 2002; 106: 3143-3421.
11. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE.Prevalence and characteristic of the metabolic syndrome in women with polycystic ovary syndrome.Journal of Clinical Endocrinology and Metabolism. 2005;90(4):1929-35.
12. Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA. The metabolic syndrome in young Korean women with polycystic vary syndrome. Diabetes Research and Clinical Practice. 2007;77(Suppl 1):5243-6.
13. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52(7):908-15.
14. Revised 2003 Consensus on diagnosis criteria and long-term health risks related to poly cystic ovarian syndrome (PCOS). Hum Reprod2004; 9: 41-47.
15. World Health Organization. Obesity: preventing and managing the global epidemic. WHO technical report series 894.Geneva: WHO;2000. Available from: http://www. bvsde. paho.org/ bvsacd/cd66/ obeprev/ indice.pdf. (10 Dec 2011)
Published
2017-12-20
How to Cite
1.
Lal M, Goyal P, Shamim S. Prevalence and Predictors of Metabolic Syndrome in Polycystic Ovarian Syndrome in Uttarakhand. International Archives of BioMedical and Clinical Research [Internet]. 20Dec.2017 [cited 22May2018];3(4):28-0. Available from: https://iabcr.org/index.php/iabcr/article/view/12